Pfizer Quality Improvement Request for Proposals: Optimizing RSV Diagnosis in Hospitalized Adults
Pfizer's grant funds projects that sustainably improve RSV testing and reporting systems for hospitalized adults, focusing on evidence-based, system-level changes to enhance patient care and surveillance.
Funder: Pfizer Inc.
Due Dates: June 25, 2026 (Submission deadline, full application)
Funding Amounts: Up to $50,000 per project; total program budget $350,000; max project length 12 months
Summary: Supports quality improvement projects implementing sustainable, system-level enhancements in RSV laboratory testing and reporting for adults hospitalized with respiratory symptoms.
Description
This competitive Quality Improvement (QI) grant program from Pfizer aims to fund projects that implement sustainable, system-level changes to improve the timely and guideline-concordant laboratory testing for respiratory syncytial virus (RSV) in adult patients admitted to emergency departments or hospitalized with respiratory symptoms. The initiative focuses on translating existing evidence into local practice by strengthening testing pathways, raising clinical awareness, and enhancing reporting mechanisms to support better patient management and surveillance. Projects should address implementation gaps such as workflow integration, sampling practices, turnaround times, and reporting. Multidisciplinary collaboration, evidence-based approaches, and measurable, sustainable improvements in RSV testing and reporting are strongly encouraged.
